newsfilter
← Latest News
Business Wire·

TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Data for Pressure-Enabled Regional Immuno-Oncology™-01 and -02 Studies

Data Further Supports the Potential of the Company's Therapeutic Platform to Improve Immunotherapy Outcomes for Patients with Liver and Pancreatic Tumors TriSalus Life Sciences®, Inc. ("TriSalus" or the